CHICAGO — Terence Rooney, MD , senior medical director for Eli Lilly, highlights recent findings from an updated integrated safety analysis of baricitinib from a long-term study of patients with rheumatoid arthritis treated up to six years.
Rooney noted that based on results from an ongoing long-term extension trial, baricitinib (Olumiant, Incyte & Eli Lilly) has maintained its previously recorded safety profile among patients with RA.
“We continued to see no difference between the two doses we evaluate – the 2 mg approved here in North America and the 4 mg dose which is available in the European Union, Japan and other counties – with respect to those event types,” he told Healio Rheumatology .
“Moving from RA, but staying with Olumiant, we have some disclosures that we are very excited about from our lupus development program,” Rooney said. “In the last couple of months, we have just started enrolling a global phase 3 development program for patients with lupus. This comes on the heels of a positive phase 2 study – the results of which we will be disclosing here – in which we compared Olumiant 2 mg and 4 mg to placebo in patients with lupus.”
Click here to view original web page at Baricitinib maintains safety profile in RA, shows promise for lupus